Rheumatoid arthritis: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• JAK 9
• TNF 9
• STAT3 0
• IL-6 2
• PI3K 0
• NLRP3 0
• CD19 18
• MAPK 0
• HIF-1 0
• NRF2 0
• mTOR 0
• IL-17 0
• STING 0
• AKT 0
• RANKL 0
• PPAR 0
• COX-2 0
• IL-1 0
• TLR4 0
• CD20 2
• TP53 0
• ERK 0
• PD-1 1
• SIRT1 0
• BCMA 7
• GLP-1 0
• MMP-9 0
• CTLA-4 1
• CTNNB1 0
• GPX4 0
• JNK 0
• SGLT2 1
• VEGF 1
• CD40 0
• HMGB1 0
• AMPK 0
• APOE 0
• AQP4 0
• CCR5 0
• FGFR 0
• IL-15 1
• METTL3 0
• PKM2 0
• TYK2 0
• CD38 1
• CGRP 0
• CXCR4 0
• IDO1 0
• PD-L1 0
• TIGIT 0
• BTK 0
• CD47 0
• EGFR 0
• HDAC 0
• IDH 0
• IL-23 0
• IL-4 0
• KEAP1 0
• MEK 0
• MYC 0

19+ intézményből 19, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  HARPNET – Harnessing Resolution Pharmacology for Next-Generation Therapeutics

  Queen Mary University of London· London, Egyesült Királyság· EU contribution 4 793 228 EUR· until 2030. szept.· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  BSSL TARGETING THERAPY TOWARDS NON-IMMUNOSUPPRESSIVE RA TREATMENT (SOL-116 - BEYOND)

  Lipum Ab· Umea, Svédország· EU contribution 7 995 375 EUR· until 2029. jún.· 3 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  PRECISION-RA: Precision Immunotherapy for Rheumatoid Arthritis

  University of Bristol· Bristol, Egyesült Királyság· EU contribution 150 000 EUR· until 2027. nov.

• European Commission (Horizon Europe) · HORIZON-ERC

  Advancing NANOmedicines to rewire tumoral MYeloid cells for next-generation cancer immunotherapies (My-NANO)

  Universiteit Gent· Gent, Belgium· EU contribution 2 499 750 EUR· until 2031. ápr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Development of Armored targeted CAR-T cells for immune reset of T cell-mediated autoimmune diseases (iCARUS)

  Weizmann Institute of Science· Rehovot, Izrael· EU contribution 150 000 EUR· until 2027. szept.

  The disease is named only in the funder's project summary, not in the title.

5 of 35 running projects, newest first. Listed amounts together: 169,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  CD40L Antagonism in Rheumatoid Arthritis (RA)

  NCT05306353· National Institute of Allergy and Infectious Diseases (NIAID)· Frissítve: 2026. júl. 20.

  “The study is being closed early due to insufficient participant enrollment across study sites.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

  NCT05246280· Navidea Biopharmaceuticals· Frissítve: 2025. jan. 23.

  “Sponsor Decision”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

  NCT07137598· Hoffmann-La Roche· Forrás

• Discontinuation of Disease-modifying Anti-rheumatic Drugs (DMARDs) in Rheumatoid Arthritis Patients Also Using TNF Inhibitors

  NCT07802678· Sint Maartenskliniek· Forrás

• Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT05814627· AbbVie· Forrás

• CD40L Antagonism in Rheumatoid Arthritis (RA)

  NCT05306353· National Institute of Allergy and Infectious Diseases (NIAID)· Forrás

• A Study of Baricitinib in Participants With Rheumatoid Arthritis

  NCT04086745· Eli Lilly and Company· Forrás

• Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)

  NCT06440629· Diakonhjemmet Hospital· Forrás

• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Eli Lilly and Company· Forrás

• Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL

  NCT07554820· Shaikh Zayed Hospital, Lahore· Forrás

• COVID-19 VaccinE Response in Rheumatology Patients

  NCT05080218· Jeffrey Curtis· Forrás

• Nonsurgical Periodontal Treatment Combined With Anti-TNF-α in Patients With Rheumatoid Arthritis and Periodontitis

  NCT06818045· Hatice Yemenoğlu· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 43
• Organoids 3
• Mendelian Randomization Analysis 98
• CRISPR-Cas Systems 1
• Gene Expression Profiling 122
• Sequence Analysis, RNA 17
• Exome Sequencing 2
• Proteomics 53
• Metabolomics 45
• Mass Spectrometry 8
• Flow Cytometry 33
• Immunohistochemistry 18
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 59
• Machine Learning 87
• Deep Learning 9
• Cohort Studies 162
• Genome-Wide Association Study 113

• Connective tissue disease-associated interstitial lung disease: immune profiling and correlation of immune cells with pulmonary function in SSc-ILD.

  Ann Med, 2026. okt.

• Single-cell mass cytometry cartography highlights systemic lupus erythematosus and Sjögren's disease immune differences.

  Front Immunol, 2026. okt.

• TMEM176B is co-expressed with TMEM176A and upregulated in peripheral blood monocytes of patients with primary Sjögren's syndrome.

  Rheumatology (Oxford), 2026. szept.

• T Cell-Derived IFN-γ Activates Ferroptosis in Lacrimal Luminal Ductal Cells via JAK-STAT Signaling in Sjögren's Disease-Related Dry Eye.

  Invest Ophthalmol Vis Sci, 2026. szept.

• T-cell subset biomarkers across the rheumatoid arthritis disease continuum: from clinical utility to adoption in daily practice.

  Rheumatology (Oxford), 2026. jún.

• Cytokine-induced PD-L1 and PD-L2 expression is preserved but reverse signalling is altered in rheumatoid arthritis fibroblast-like synoviocytes.

  Arthritis Res Ther, 2026. jún.

• Elevated ST2+ Tregs in RA-ILD: correlation with pulmonary fibrosis and the IL-33/ST2/AREG axis.

  Arthritis Res Ther, 2026. máj.

• Dual dynamics of persistence and recruitment characterise the ACPA-expressing B cell response in rheumatoid arthritis.

  Ann Rheum Dis, 2026. ápr.

• Alterations in Circulating Progenitor Cell Composition in Rheumatoid Arthritis.

  Cells, 2026. ápr.

• RA and PsA synovial tissue single-cell analysis demonstrates differential fibroblast populations with distinct phenotypes and functional capacities.

  Ann Rheum Dis, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.